ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
17.52
+0.08 (0.46%)
At close: May 12, 2025, 4:00 PM
17.50
-0.02 (-0.11%)
After-hours: May 12, 2025, 5:05 PM EDT
ACADIA Pharmaceuticals Employees
As of December 31, 2024, ACADIA Pharmaceuticals had 654 total employees, including 653 full-time and 1 part-time employees. The number of employees increased by 56 or 9.36% compared to the previous year.
Employees
654
Change (1Y)
56
Growth (1Y)
9.36%
Revenue / Employee
$1,523,369
Profits / Employee
$349,974
Market Cap
2.93B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACAD News
- 4 days ago - ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 5 days ago - Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview - Business Wire
- 7 days ago - Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference - Business Wire
- 19 days ago - Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med - Business Wire
- 2 months ago - Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study - Business Wire